Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

Rhea-AI Summary

Quantum BioPharma (NASDAQ: QNTM) appointed Dr. Salvatore Napoli as Principal Investigator for a planned Phase 2 trial of Lucid-21-302 (Lucid-MS), a first-in-class neuroprotective candidate targeting demyelination in multiple sclerosis.

The company intends to submit an IND to the FDA in the coming weeks; the Phase 2 study will evaluate efficacy, safety, and tolerability subject to regulatory clearance.

News Market Reaction – QNTM

-11.95%

38 alerts

-11.95% Session close to close

+33.9% Peak Tracked

-7.0% Trough Tracked

$19.36M Market Cap

0.7x Rel. Volume

In the Mar 26 session, QNTM declined 11.95%, reflecting a significant negative market reaction. Argus tracked a peak move of +33.9% during that session. Argus tracked a trough of -7.0% from its starting point during tracking. Our momentum scanner triggered 38 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -11.9% in the session following this news. The decline reflects a recurring patter...

Analysis

The stock dropped -11.9% in the session following this news. The decline reflects a recurring pattern where Quantum BioPharma’s stock sometimes weakened even on program‑advancing news, as seen with the -11.51% move after Lucid‑MS toxicity completion. Despite the positive signal of a planned Phase 2 Lucid‑MS trial and appointment of a seasoned principal investigator, the share price already traded well below the $12.76 200‑day MA and far under the $38.25 52‑week high, indicating prior pressure that may have amplified selling around this update.

Key Figures

Trial phase: Phase 2 Clinical experience: Over 20 years

2 metrics

Trial phase Phase 2 Planned Lucid-MS clinical trial in multiple sclerosis

Clinical experience Over 20 years Dr. Napoli’s MS clinical and research experience

Historical Context

5 past events · Latest: Mar 23 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 23	Clinical trial data	Positive	+38.4%	Peer-reviewed Unbuzzd trial shows faster BAC reduction and symptom improvement.
Dec 23	Preclinical completion	Positive	-11.5%	Completion of 180-day toxicity and toxicokinetic studies for Lucid-MS program.
Dec 10	Private placement	Negative	-7.3%	Small private placement, related-party participation, and debt settlement via share issuance.
Dec 01	Litigation coverage	Negative	-11.7%	TV segment on USD $700M stock-manipulation lawsuit involving major Canadian banks.
Nov 28	Litigation coverage	Negative	-15.0%	Repeat airing of investigative series part on alleged stock manipulation of QNTM.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

News on legal and financing topics has generally coincided with negative price moves, while clinical or product-positive updates have sometimes produced strong rallies but also one notable selloff, indicating inconsistent reactions to R&D progress.

Recent Company History

Over the past six months, Quantum BioPharma issued several material updates. A Mar 23, 2026 peer‑reviewed Unbuzzd trial publication coincided with a 38.39% gain, contrasting with an -11.51% move after the Dec 23, 2025 Lucid‑MS toxicity completion update. A Dec 10, 2025 private placement and debt settlement aligned with a -7.26% decline. Two late‑November and early‑December 2025 investigative TV segments about a stock‑manipulation lawsuit saw further drops of -11.65% and -14.99%. Today’s Phase 2 planning step fits this ongoing Lucid‑MS development narrative.

Key Terms

demyelination, multiple sclerosis, principal investigator, investigational new drug (ind), +4 more

8 terms

demyelination medical

"investigational therapy being developed to target demyelination in Multiple Sclerosis"

Demyelination is the loss or damage of the protective sheath (myelin) that surrounds nerve fibers, similar to how stripped insulation makes electrical wires slower and more error-prone. It matters to investors because diseases or treatments that cause or prevent demyelination can drive clinical trial outcomes, regulatory scrutiny, and long-term costs for healthcare companies; evidence of demyelination can change a drug’s safety profile and therefore a company’s market value.

multiple sclerosis medical

"target demyelination in Multiple Sclerosis (MS)"

A chronic neurological disease in which the immune system damages the protective coating (like insulation on electrical wires) around nerves, disrupting signals between the brain and body and causing symptoms such as numbness, weakness, vision problems, fatigue and mobility issues. It matters to investors because the unpredictability and long-term nature of the condition drive ongoing demand for treatments, influence the value of companies developing therapies, affect healthcare costs and shape regulatory and reimbursement decisions.

principal investigator technical

"announced the appointment of Dr. Salvatore Napoli, MD, as Principal Investigator"

A principal investigator is the lead person responsible for overseeing a research project or study, ensuring it stays on track and meets its goals. In the context of investments, this role can be likened to the person in charge of a team or initiative, making key decisions and managing resources. Understanding who the principal investigator is can help investors assess the reliability and credibility of a project or research effort.

investigational new drug (ind) regulatory

"intends to submit an Investigational New Drug (IND) application for Lucid-MS"

An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.

u.s. food and drug administration (fda) regulatory

"application for Lucid-MS to the U.S. Food and Drug Administration (FDA)"

The U.S. Food and Drug Administration (FDA) is a government agency responsible for protecting public health by ensuring the safety and effectiveness of food, medicines, vaccines, and other health-related products. For investors, the FDA’s decisions can significantly impact companies in the healthcare and food industries, as approval or rejection of products can influence a company's success and stock performance.

neuroprotective medical

"first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism"

Neuroprotective describes a drug, treatment, or compound that helps protect nerve cells from injury, degeneration, or death and can slow or prevent loss of brain or nervous-system function. For investors, claims of neuroprotective activity matter because they suggest a therapy could address chronic or progressive conditions (like those that worsen over time), potentially creating long-term demand, higher development hurdles, and regulatory scrutiny; think of it as a shield for neurons that could change a product’s market value.

new chemical entity (nce) regulatory

"It is a patented New Chemical Entity (NCE) that has been shown"

A new chemical entity (NCE) is a medication’s active molecule that has never been approved or marketed before anywhere; think of it as a brand‑new recipe rather than a tweak to an existing one. For investors, NCEs matter because they can offer strong commercial upside and regulatory exclusivity if proven safe and effective, but they also carry higher scientific and approval risk compared with drugs that are modifications of known compounds.

mechanism of action medical

"neuroprotective compound with a unique mechanism of action for the treatment of MS"

Mechanism of action describes how a drug, therapy, or medical product produces its effect in the body—the specific steps, targets, and biological processes it engages, like a key fitting into a lock to open a door. Investors care because a clear, well-understood mechanism reduces scientific uncertainty, supports regulatory approval and market confidence, and helps predict safety, effectiveness and additional uses, all of which influence a product’s commercial potential and a company’s valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Highlights advancement of first-in-class neuroprotective candidate targeting demyelination

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced the appointment of Dr. Salvatore Napoli, MD, as Principal Investigator for its planned Phase 2 clinical trial evaluating Lucid-21-302 (Lucid-MS), an investigational therapy being developed to target demyelination in Multiple Sclerosis (MS).

Dr. Salvatore Napoli, is an internationally recognized neurologist and key opinion leader in MS, with over 20 years of clinical and research experience. He is President and Medical Director of the Neurology Center of New England and the MS Center of New England, where he leads advanced clinical and research programs in MS. Dr. Napoli completed specialized fellowship training in MS and neuroimmunology at the Brigham and Women’s Hospital and has held academic appointments at Harvard Medical School. He has served as a principal investigator and sub-investigator on numerous clinical trials in MS, and his work has focused on advancing innovative approaches to treating neurodegenerative disorders.

Quantum BioPharma intends to submit an Investigational New Drug (IND) application for Lucid-MS to the U.S. Food and Drug Administration (FDA) in the coming weeks. The IND application includes the design of the Phase 2 trial of Lucid-MS. Subject to regulatory clearance of the IND, the planned clinical trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with MS.

“We are pleased to collaborate with Dr. Napoli as we advance our clinical development program,” said Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum BioPharma. “Disease progression and demyelination remain areas of significant unmet medical need in MS, and Dr. Napoli’s expertise will be invaluable as we prepare for clinical evaluation of Lucid-MS.”

Zeeshan Saeed, CEO of Quantum BioPharma added, “The appointment of Dr. Napoli represents a key milestone as we advance Lucid-MS toward clinical evaluation. As we prepare for a planned Phase 2 study, our focus is on targeting biological processes associated with disease progression in MS. We believe this program underscores the potential of our approach to addressing areas of high unmet need in neurodegenerative disease.”

“I look forward to working with Quantum BioPharma to evaluate this investigational approach with Lucid-MS,” said Dr. Napoli. “Continued research into therapies targeting mechanisms of MS disease progression—including demyelination and the potential for remyelination—is critically important for patients and remains an unmet need.”

Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of MS. It is a patented New Chemical Entity (NCE) that has been shown in preclinical models to prevent demyelination, a hallmark of MS and other neurodegenerative diseases, which is characterized by damage to the myelin sheath surrounding nerve fibers.

About Quantum BioPharma Ltd.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“UWI”), led by industry veterans. Quantum BioPharma retains ownership of 19.86% (as of September 30, 2025) of UWI at www.unbuzzd.com. The agreement with UWI also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Additionally, Quantum BioPharma retains a large tax loss carry forward of approximately C$130 million and could be utilized in the future to offset tax payable obligations against future profits. Quantum BioPharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Forward-Looking Information

Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward- looking information, except as required by applicable law.

Contacts:

Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (416) 854-8884

Investor Relations
Email: ir@quantumbiopharma.com, info@quantumbiopharma.com
Website: www.quantumbiopharma.com

FAQ

Who is the Principal Investigator for Quantum BioPharma's planned Phase 2 Lucid-MS trial (QNTM)?

Dr. Salvatore Napoli is the appointed Principal Investigator for the planned Phase 2 Lucid-MS trial. According to the company, Dr. Napoli brings over 20 years of MS clinical and research experience and leads the Neurology Center of New England and MS Center of New England.

When will Quantum BioPharma (QNTM) submit the IND for Lucid-21-302 (Lucid-MS)?

Quantum BioPharma intends to submit an IND for Lucid-MS to the FDA in the coming weeks. According to the company, the IND package includes the planned Phase 2 trial design and supports regulatory review before study start.

What will the planned Phase 2 Lucid-MS trial (QNTM) evaluate in people with MS?

The planned Phase 2 trial will evaluate efficacy, safety, and tolerability of Lucid-MS in people with MS. According to the company, the study design in the IND focuses on clinical evaluation of neuroprotective effects related to demyelination.

What is Lucid-21-302 (Lucid-MS) and how does it aim to treat MS for QNTM investors?

Lucid-MS is a first-in-class, non-immunomodulatory neuroprotective compound targeting demyelination. According to the company, preclinical models showed prevention of demyelination and the drug is a patented new chemical entity aimed at disease-progression mechanisms.

Does the planned Phase 2 Lucid-MS trial (QNTM) have regulatory approval to start?

No, the Phase 2 trial is subject to regulatory clearance and does not yet have approval to start. According to the company, the IND submission is imminent and study commencement depends on FDA clearance of that IND.